Agreements reached under this partnership
Business Alliances- 1
FRONTEO will use DDAIF, its AI drug discovery platform, to analyze disease-related target molecules for each research theme and select multiple candidate combinations of targets considered promising for development as bispecific antibodies
- 2
Chiome Bioscience will use DoppeLib™ to generate bispecific antibody candidates and evaluate their binding activity, function and other characteristics
- 3
For promising candidates, the parties will advance optimization and validation while taking into consideration efficacy, safety and suitability as pharmaceuticals
- 4
The two companies will conduct joint research on multiple research themes
- 5
For the antibody drug candidates generated, the parties will seek to pursue joint development or prompt out-licensing to pharmaceutical companies and other parties
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Create bispecific antibody drug candidates during fiscal 2027
The impact on results for the fiscal year ending December 2026 is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | FRONTEO, Inc. |
| Alliance partner's business activities | Life sciences AI, risk management, DX and other businesses utilizing the internally developed equation-driven AI system KIBIT |
| Alliance partner's location | Minato-ku, Tokyo |
| Alliance partner's capital | ¥915.057 million (as of 30 June 2026) |
| Type of alliance | Business Alliances |
| Details of the alliance | FRONTEO will use DDAIF, its AI drug discovery platform, to analyze disease-related target molecules for each research theme and select multiple candidate combinations of targets considered promising for development as bispecific antibodies, Chiome Bioscience will use DoppeLib™ to generate bispecific antibody candidates and evaluate their binding activity, function and other characteristics, For promising candidates, the parties will advance optimization and validation while taking into consideration efficacy, safety and suitability as pharmaceuticals, The two companies will conduct joint research on multiple research themes, For the antibody drug candidates generated, the parties will seek to pursue joint development or prompt out-licensing to pharmaceutical companies and other parties |
| Numerical targets under the alliance | Create bispecific antibody drug candidates during fiscal 2027 |
| Contract Date | 3 September 2026 |
| Alliance start date | 3 September 2026 |
| Impact on Business Performance | The impact on results for the fiscal year ending December 2026 is expected to be immaterial. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To integrate FRONTEO's AI drug discovery support service for identifying novel targets with the Company's antibody drug discovery technology, enabling the continuous advancement of research from target identification through the creation and validation of antibody candidates.